Literature DB >> 1778109

Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide.

Y Aoki1.   

Abstract

The variation of endogenous insulin secretion in association with fasting plasma glucose (FPG) level and the modality of treatment was assessed using serum C-peptide levels before and after breakfast and the corrected value of 24-h urinary C-peptide (24 h-UCP) in inpatients with non-insulin-dependent diabetes mellitus. The corrected value calculated as 24 h-UCP/(urinary C-peptide to creatinine clearance (CCP/CCR) ratio in the fasting state x 10) was correlated with the sum of day-long serum C-peptide levels (r = 0.93) more closely than the measured value of 24 h-UCP (r = 0.79) in 9 patients. In 52 patients treated with diet alone, 38 with sulfonylurea and 28 with insulin, fasting serum C-peptide level did not vary with FPG level, and the increment of serum C-peptide level after breakfast and the corrected value of 24 h-UCP decreased with the rise in FPG level in each treatment. These indexes were the lowest in insulin treatment among the patients with similar FPG levels. In conclusion, 24 h-UCP was demonstrated to be able to reflect day-long endogenous insulin secretion more faithfully after the correction with the CCP/CCR ratio. It was estimated that the insulin response to breakfast and day-long insulin secretion decreased with the rise in FPG level, but basal insulin secretion was maintained over a wide range of FPG levels in each treatment. Endogenous insulin secretion seemed to be somewhat suppressed or rested by exogenous insulin in insulin-treated patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1778109     DOI: 10.1016/0168-8227(91)90017-8

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  5 in total

1.  Relationship between modified homeostasis model assessment/correlative serum factors and diabetic retinopathy among type 2 diabetics with insulin therapy in Guangzhou, China.

Authors:  Li Hu; Dong-Hao Li
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

Review 2.  The clinical utility of C-peptide measurement in the care of patients with diabetes.

Authors:  A G Jones; A T Hattersley
Journal:  Diabet Med       Date:  2013-07       Impact factor: 4.359

3.  Analysis of factors influencing postprandial C-peptide levels in Japanese patients with type 2 diabetes: Comparison with C-peptide levels after glucagon load.

Authors:  Shogo Funakoshi; Shimpei Fujimoto; Akihiro Hamasaki; Hideya Fujiwara; Yoshihito Fujita; Kaori Ikeda; Shiho Takahara; Yutaka Seino; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2011-11-30       Impact factor: 4.232

4.  C-Peptide and vascular complications in type 2 diabetic subjects.

Authors:  Seok Man Son
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

5.  Post-glucose-load urinary C-peptide and glucose concentration obtained during OGTT do not affect oral minimal model-based plasma indices.

Authors:  Sjaam Jainandunsing; J L Darcos Wattimena; Trinet Rietveld; Joram N I van Miert; Eric J G Sijbrands; Felix W M de Rooij
Journal:  Endocrine       Date:  2015-11-02       Impact factor: 3.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.